Affiliation:
1. Department of Microbiology, Institute of Tropical Medicine, Antwerp, Belgium,1 and
2. Armed Forces Institute of Pathology, Washington, D.C. 20306-60002
Abstract
ABSTRACT
Buruli ulcer (BU), caused by
Mycobacterium ulcerans
, was recently recognized by the World Health Organization as an important emerging disease. While antimycobacterial therapy is often effective for the earliest nodular or ulcerative lesions, medical management of BU lesions in patients presenting for treatment is usually disappointing, leaving wide surgical excision the only alternative. Advanced ulcerated lesions of BU rarely respond to antimycobacterial agents; however, perioperative administration of such drugs may prevent relapses or disseminated infections. Clarithromycin possesses strong activity in vitro and in vivo against most nontuberculous mycobacteria. In this study we determined the antimycobacterial activity of this drug in vitro against 46 strains of
M. ulcerans
isolated from 11 countries. The MIC of clarithromycin was determined at pH 6.6 (on 7H11 agar) and at pH 7.4 (on Mueller-Hinton agar). The MICs ranged from 0.125 to 2 μg/ml at pH 6.6 and from <0.125 to 0.5 μg/ml at pH 7.4. For the majority of the strains, geographic origin did not play a significant role. Thirty-eight strains (83%) were inhibited by 0.5 μg/ml at pH 7.4. These MICs are below peak therapeutic concentrations of clarithromycin obtainable in blood. These results suggest that clarithromycin is a promising drug both for the treatment of early lesions of
M. ulcerans
and for the prevention of hematogenous dissemination of the etiologic agent during and after surgery. Studies should be initiated to evaluate the effects of clarithromycin in combination with ethambutol and rifampin on
M. ulcerans
both in vitro and in experimentally infected mice. Multidrug regimens containing clarithromycin may also help control the secondary bacterial infections sometimes seen in BU patients, most importantly osteomyelitis.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference39 articles.
1. Abalos F. et al. Unpublished data.
2. Mycobacterium ulcerans infection.;Abalos F.;Am. J. Trop. Med. Hyg.,1997
3. L’ulcère de Buruli, une maladie mycobactérienne importante et en recrudescence au Bénin.;Aguiar J.;Bull. Séances Acad. R. Sci. Outre-Mer,1997
4. Les ulcères de Buruli en zone rurale au Bénin: prise en charge de 635 cas.;Aguiar J.;Med. Trop.,1997
5. Mycobacterium genavense infection presenting as a solitary brain mass in a patient with AIDS: case report and review.;Berman S. M.;Clin. Infect. Dis.,1994
Cited by
77 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. L’infection à Mycobacterium ulcerans ou ulcère de Buruli;Bulletin de l'Académie Nationale de Médecine;2023-10
2. Current Progress and Prospects for a Buruli Ulcer Vaccine;Vaccines for Neglected Pathogens: Strategies, Achievements and Challenges;2023
3. Treatment of Buruli Ulcer;Leprosy and Buruli Ulcer;2022
4. Pharmacologic management of Mycobacterium ulcerans infection;Expert Review of Clinical Pharmacology;2020-04-02
5. Buruli Ulcer;Neglected Tropical Diseases;2019-08-02